A Phase 2, Open Label, Ascending Dose Study of ACE-536 for the Treatment of Anemia in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) - A536-03

Trial Profile

A Phase 2, Open Label, Ascending Dose Study of ACE-536 for the Treatment of Anemia in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) - A536-03

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Luspatercept (Primary)
  • Indications Anaemia
  • Focus Therapeutic Use
  • Acronyms PACE-MDS
  • Sponsors Acceleron Pharma
  • Most Recent Events

    • 25 Jun 2017 Results of parent and extension (n= 115; as of 9 sep 2016) studies presented at the 22nd Congress of the European Haematology Association
    • 23 Jun 2017 Interim results from this trial presented at the 22nd Congress of the European Hematology Association (EHA) 2017, as per an Acceleron Pharma media release.
    • 23 Jun 2017 Interim results published in an Acceleron Pharma Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top